# A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects

> **NCT05045313** · PHASE1 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Warfarin sodium tablets
- **DRUG:** Digoxin tablet
- **DRUG:** Probenecid tablets
- **DRUG:** DBPR108 tablets

## Key facts

- **NCT ID:** NCT05045313
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-20
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05045313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05045313, "A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05045313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*